DocDollars

Aimmune Therapeutics, Inc.

NJ · United States · Reporting entity ID 100000776814

Total reported 2019–2025
$15.1M
#390 of 2,960 reporting companies — 0% of all reported industry payments
$5.50M in general payments across 80,705 records, plus $9.55M in research funding across 3,421 records.

How it breaks down

General payments $5,503,203
Research funding $9,553,798

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Aimmune Therapeutics, Inc. reported $15.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #390 of 2,960 reporting companies. 63% of that was research funding and 37% general payments such as consulting, speaking, food and travel. 80,705 general payment records and 3,421 research records were filed.

Common questions about Aimmune Therapeutics, Inc.

How much has Aimmune Therapeutics, Inc. paid US doctors?

Aimmune Therapeutics, Inc. reported $15,057,000 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $5,503,203 in general payments, $9,553,798 in research funding.

How does Aimmune Therapeutics, Inc. rank among drug and device companies?

It ranks #390 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Aimmune Therapeutics, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.